Binary code with a blue background

Turning a Failed Bioequivalence Study into a Successful Regulatory Outcome 

1 minute read

Published: November 16th, 2026

When a bioequivalence study fails to meet regulatory criteria, understanding why is critical for successful development and approval. 

In this case study, Phastar helped investigate a failed European bioequivalence study, identify the statistical factors behind the outcome, and support a successful regulatory strategy. 

Download the full case study to discover how Phastar helps sponsors address regulatory challenges through expert statistical consultancy and evidence-based decision-making. 

Related articles

From Rescue Study to Strategic Partnership: Accelerating Regulatory Submission Through Reliable Statistical Delivery

From Rescue Study to Strategic Partnership: Accelerating Regulatory Submission Through Reliable Statistical Delivery

November 16th, 2026 1 minute read

When clinical development programs face quality concerns, resource shortages, or submission risks, sponsors need a pa...

Independent DMC Support and Interim Analysis for an ALS Clinical Trial 

Independent DMC Support and Interim Analysis for an ALS Clinical Trial 

November 16th, 2026 1 minute read

Data Monitoring Committees play a vital role in safeguarding patient safety and supporting informed decision-making t...

Supporting a Global HIV Development Program Through Independent IDMC Oversight and Statistical Leadership

Supporting a Global HIV Development Program Through Independent IDMC Oversight and Statistical Leadership

November 16th, 2026 1 minute read

As clinical development programmes grow in scale and complexity, sponsors need confidence that safety and efficacy re...